Clinical Study Of Dexamethasone Implant (Ozurdex) Combined With Conbercept In The Treatment Of Macular Edema Secondary To Retinal Vein Obstruction

Objective:To evaluate the clinical efficacy and safety of dexamethasone implant(Ozurdex)combined with Conbercept and individual agents in the treatment of retinal vein obstruction with macular edema(RVO-ME).Method:One hundred and forty-four patients(144 eyes)with CRVO-ME were divided into two groups according to blood type and non-blood type.There were 24 patients in the combination group(24 eyes),22 patients in the Ozurdex group(22 eyes)and 23 patients in the Conbercept group(23 eyes).There were 25 patients in the combination group(25eyes),24 patients in the Ozurdex group(24 eyes)and 26 patients in the Conbercept group(26 eyes).A total of 168 patients(168 eyes)with BRVO-ME were studied according to blood type deficiency and non-blood type.There were 28 patients in the combination group(28 eyes),25 patients in the Ozurdex group(25 eyes)and 25 patients in the Conbercept group(25 eyes).There were 33 cases(33 eyes)in the combination group,29 cases(29 eyes)in the Ozurdex group and 28 cases(28 eyes)in the Conbercept group.Conbercept was administered 7 days after intravitreal injection of Ozurdex in the combination group.The optimal corrected visual acuity(BCVA),macular fovea thickness(CFT),macular volume(MV),mean retinal thickness(CRT),injection times,intraocular pressure(IOP)and complications were compared among the three groups.Results:BCVA,MV,CFT and CRT of CRVO-ME and BRVO-ME patients after treatment were all better than before treatment,and the difference was statistically significant(P<0.05).The improvement of visual acuity and the decrease of MV in the Conbercept and Ozurdex groups were better than those in the corresponding group,with statistical significance(P < 0.05).There was no statistical significance in IOP,CFT and CRT among the patients with and without anemic blood group.During the 6-month study,the mean number of injections for CRVO-ME patients was 3.5 in the Conbercept group,1in the Ozurdex group,and 2.5 in the combination group.Patients with BRVO-ME had3.1 times,1 time and 2.3 times,respectively.Conclusion:Ozurdex combined with Conbercept in the treatment of RVO-ME can improve BCVA,MV,CFT and CRT in patients with relatively few injection times,and the therapeutic effect is significantly better than that of Ozurdex or Conbercept alone.The three groups of data can meet the requirements of safety and effectiveness.